Blood NfL: A biomarker for disease severity and progression in Parkinson disease

Chin-Hsien Lin; Cheng-Hsuan Li; Kai-Chien Yang; Fang-Ju Lin; Chau-Chung Wu; Jen-Jie Chieh; Ming-Jang Chiu

doi:10.1212/WNL.0000000000008088

Full PDF

Short Form

Citation

Permissions

Make Comment

See Comments

Downloads

176

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)

Non-AAN Member subscribers: Sign in with subscriber credentials

Purchase access

AAN members must change their passwords on the AAN site

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here

Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.

Disputes & Debates: Rapid online correspondence

Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease
Anouke van Rumund, MD, Radboudumc

Tainá M. Marques, MSc, Radboudumc

Rianne A.J. Esselink, MD, PhD, Radboudumc

Bastiaan R. Bloem, MD, PhD, Radboudumc

Marcel M. Verbeek, PhD, Radboudumc
Published November 22, 2019

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

Stay timely. Submit only on articles published within the last 8 weeks.
Do not be redundant. Read any comments already posted on the article prior to submission.
200 words maximum.
5 references maximum. Reference 1 must be the article on which you are commenting.
5 authors maximum. Exception: replies can include all original authors of the article.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Authors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Main menu

User menu

Search

Blood NfL

A biomarker for disease severity and progression in Parkinson disease

Citation Manager Formats

Purchase access

Disputes & Debates: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

Topics Discussed

Alert Me

Articles

About

Submit

Subscribers

Main menu

User menu

Search

Share

Blood NfL

A biomarker for disease severity and progression in Parkinson disease

Citation Manager Formats

Share

Log in using your username and password

Purchase access

Disputes & Debates: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

Related Articles

Topics Discussed

Alert Me

Articles

About

Submit

Subscribers